Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03584516 · ClinicalTrials.gov registry record · Phase 2
GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
A Phase 2 study, sponsored by Incyte Corporation.
- Terminated
- Registry status
- Phase 2
- Development phase
- 155
- Enrollment target
NCT03584516 is a Phase 2 study that was terminated before completion, run by Incyte Corporation. The registered enrollment target is 155 participants.
The verdict
NCT03584516, a Phase 2 study, was terminated before completion, sponsored by Incyte Corporation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 155 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy and safety of itacitinib in combination with corticosteroids as first-line treatment for moderate or severe chronic graft-versus-host disease (cGVHD).
Interventions
- DRUG Placebo
- DRUG Prednisone
- DRUG Methylprednisolone
- DRUG Itacitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2019-01-17 |
| Est. Completion | 2023-11-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03584516
The ClinicalTrials.gov registry entry for NCT03584516 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 155 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT03584516 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03584516 about?
NCT03584516 is a clinical study titled "GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease". The purpose of this study is to assess the efficacy and safety of itacitinib in combination with corticosteroids as first-line treatment for moderate or severe chronic graft-versus-host disease (cGVHD).
What is the current status of trial NCT03584516?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 155 participants. The study started on 2019-01-17. Estimated completion is 2023-11-03.
What interventions are being tested in trial NCT03584516?
The interventions under investigation include: Placebo (DRUG), Prednisone (DRUG), Methylprednisolone (DRUG), Itacitinib (DRUG).
Who is sponsoring clinical trial NCT03584516?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.